AstraZeneca

AstraZeneca and Oracle Health and Life Sciences announced a global AI collaboration combining AstraZeneca's clinical development and regulatory expertise with Oracle's real-world data, cloud infrastructure and AI-enabled clinical capabilities, aiming to speed clinical research and bring evidence into care workflows. The stated early areas include clinical trial recruitment, earlier diagnosis, drug-safety monitoring and real-world evidence across a medicine's lifecycle, spanning oncology, cardiovascular, renal and metabolic, respiratory and immunology, and rare disease. The first programme focuses on hypertension care and clinical research in Abu Dhabi with healthcare company M42; the companies signed a non-binding term sheet and disclosed no financials.

AstraZeneca and Oracle Health and Life Sciences announced a global AI collaboration combining AstraZeneca's clinical development and regulatory expertise with Oracle's real-world data, cloud infrastructure and AI-enabled clinical capabilities, aiming to speed clinical research and bring evidence into care workflows. The stated early areas include clinical trial recruitment, earlier diagnosis, drug-safety monitoring and real-world evidence across a medicine's lifecycle, spanning oncology, cardiovascular, renal and metabolic, respiratory and immunology, and rare disease. The first programme focuses on hypertension care and clinical research in Abu Dhabi with healthcare company M42; the companies signed a non-binding term sheet and disclosed no financials.

AstraZeneca signed a new strategic drug discovery collaboration and licensing agreement with AI therapeutics company insitro to identify novel targets and advance new programmes for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. insitro will apply its Virtual Human AI platform, which combines large-scale human and cellular data with AI-enabled target identification and medicine design, to identify causal disease biology and move AstraZeneca-nominated targets from discovery to development candidate. insitro receives a $40 million upfront payment and is eligible for up to approximately $1.46 billion in development and commercial milestones plus single-digit royalties, while AstraZeneca holds exclusive worldwide rights to selected programmes.

AstraZeneca signed a new strategic drug discovery collaboration and licensing agreement with AI therapeutics company insitro to identify novel targets and advance new programmes for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. insitro will apply its Virtual Human AI platform, which combines large-scale human and cellular data with AI-enabled target identification and medicine design, to identify causal disease biology and move AstraZeneca-nominated targets from discovery to development candidate. insitro receives a $40 million upfront payment and is eligible for up to approximately $1.46 billion in development and commercial milestones plus single-digit royalties, while AstraZeneca holds exclusive worldwide rights to selected programmes.